Randomized trial demonstrates efficacy of BCMA-specific CAR-T cells in patients with relapsed multiple myeloma, highlighting a potential breakthrough treatment.
Key Points
To assess the safety and efficacy of BCMA-targeted CAR-T cell therapy in refractory/relapsed multiple myeloma.
Single arm clinical trial
19 patients with refractory/relapsed multiple myeloma
Median follow-up of 208 days
100% objective response rate (ORR) observed
18 out of 19 (95%) patients achieved complete or near complete remission
14 patients experienced mild to manageable cytokine release syndrome, with 1 case of grade 4